A Single-Dose, Randomized, Three-way, Partially Blinded Crossover Study to Compare the Pharmacokinetics and Bioavailability of Ceftriaxone Administered as a 1 Gram Intravenous Infusion, a 1 Gram Subcutaneous Infusion and a 2 Gram Subcutaneous Infusion in Healthy Adult Subjects

Trial Profile

A Single-Dose, Randomized, Three-way, Partially Blinded Crossover Study to Compare the Pharmacokinetics and Bioavailability of Ceftriaxone Administered as a 1 Gram Intravenous Infusion, a 1 Gram Subcutaneous Infusion and a 2 Gram Subcutaneous Infusion in Healthy Adult Subjects

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Ceftriaxone (Primary) ; Ceftriaxone
  • Indications Bacterial infections
  • Focus Pharmacokinetics; Registrational
  • Sponsors scPharmaceuticals; Sensile Medical
  • Most Recent Events

    • 31 Oct 2016 Results presented at IDWeek 2016, as per scPharmaceuticals media release.
    • 30 Oct 2016 Results assessing pharmacokinetic comparision of subcutaneous administration of ceftriaxone verses intravenous administration presented at the IDWeek 2016.
    • 06 Jun 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top